Flamel Technologies (FLML): Sodium Oxybate Getting Back On Track - Needham

Leerink Partners analyst, Jason Gerberry reiterated his Outperform rating on shares of Flamel Technologies (NASDAQ: FLML) after the company highlighted that the pivotal Phase 3 study (REST-ON) for the company's once-nightly sodium oxybate (similar to JAZZ’s Xyrem) commenced after a several month delay.

At the event, mgmt emphasized 3 key features it believes will differentiate m-SXB:

1) once-nightly dosing vs. Xyrem's twice-nightly dosing.

2) tamper-resistant packaging - FLML plans to package m-SXB in child resistant packaging and emphasized QD dosing mitigates the issue of having an unattended dose on the pts nightstand

3) tolerability benefit - mgmt believes less water consumed with QD dosed product could cut down on the frequency of nocturnal enuresis (bed wetting).

Key upcoming events for FLML include: (1) possible update on Xyrem 2.0 by end-2016, per JAZZ; (2) Xyrem patent updates over the next 12 months.

No change to the price target of $16.

For an analyst ratings summary and ratings history on Flamel Technologies click here. For more ratings news on Flamel Technologies click here.

Shares of Flamel Technologies closed at $13.36 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)